Seed startup

Who invested in Oxford Immune Algorithmics

One round we have observed, with the one investor named in it. Every figure came from a named source, and where the company reported a raise to the SEC itself, that is shown beside it.

Medical Devices

Funding summaryUpdated 26 Oct 2026

$7.1Mraised across 1 round since 2021, from 1 source

Latest round
Seed, $7.1MApr 2021
Investors
1
See who backed them

The rounds

  1. Apr 2021
    Seed$7.1M

    Source recorded

Founders and team

From Oxford Immune Algorithmics's own website: 4 on the team.

  • Allan BezansonDirector
  • Dr. Pradip BanerjeeDirector
  • John CullenBoard Chair
  • Prof. Jesper N. TegnérDirector

AdvisersAbel ArchundiaDr. Andrew KingDr. Corey CutlerDr. Hamid SadriDr. Jason BermanDr. Narsis A. KianiDr. Rolf PorscheDr. Sam ToneyDr. Syed Ahsan RazaMartin KorbmacherPamela WinsorProf. Patrick TigheProf. Petter BrodinProf. Weizi LiRembert de VillaTony Cambridge

Everyone who backed them

Creative Destruction LabAccelerator1round

Missing a round, or an investor who was in one? Tell us.

Quick answers about Oxford Immune Algorithmics

Who invested in Oxford Immune Algorithmics?

Oxford Immune Algorithmics's investors include Creative Destruction Lab.

How much has Oxford Immune Algorithmics raised?

Oxford Immune Algorithmics has raised $7.1M across 1 round since 2021.

When did Oxford Immune Algorithmics last raise?

Oxford Immune Algorithmics's most recent round was a Seed of $7.1M in Apr 2021.

What was Oxford Immune Algorithmics's biggest round?

Its most recent round, $7.1M in Apr 2021, is also its largest on record.

Who backed Oxford Immune Algorithmics first?

Oxford Immune Algorithmics's first round on record, in Apr 2021, was backed by Creative Destruction Lab.

What stage is Oxford Immune Algorithmics at?

Oxford Immune Algorithmics's latest named round is a Seed, in Apr 2021.

Companies like Oxford Immune Algorithmics

In the same sector, and raised in the last eighteen months.

Find investors like these

Search every investor by what they have actually funded, then narrow to your stage and market. Free.